Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severityOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked which gut microbes and metabolites are altered at the onset of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation. Researchers prospectively collected stool samples and compared patients at aGVHD onset with non-GVHD patients. They measured fecal short-chain fatty acid (SCFA) profiles. Microbiota composition was assessed by high-throughput DNA sequencing and real-time quantitative PCR.
Who was studied?
The cohort consisted of human patients who underwent allogeneic hematopoietic stem cell transplantation. Stool samples taken at the time of aGVHD onset were compared against samples from patients who did not develop GVHD. Analyses were stratified by gastrointestinal aGVHD severity. The work focused on the microbial and metabolic state at the specific moment of disease onset rather than earlier time points.
What were the most important findings?
Microbiota alterations were highly specific to gastrointestinal aGVHD severity. Bacterial biomass and alpha diversity were lower in severe aGVHD. Severe aGVHD at onset showed depletion of anaerobic Lachnospiraceae, especially the Blautia genus, and Ruminococcaceae. The main SCFAs dropped sharply: acetate by 75.8 percent, propionate by 95.8 percent, and butyrate by 94.6 percent. Mild aGVHD patients kept propionate levels and Blautia propionate producers. Butyrate fell in all gastrointestinal aGVHD stages, marking it as a potential diagnostic signal.
What are the greatest implications of this study?
The results identify specific bacteria and metabolites tied to aGVHD severity, suggesting that fecal SCFAs, particularly butyrate, could serve as diagnostic and pathophysiologic markers at disease onset. This supports interest in restoring protective microbiota as a therapeutic approach. Because the study is observational and captures a single onset time point, it shows association rather than proof that SCFA loss drives severe disease. Larger validation is needed before clinical use.